6 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
EURopean Endeavour for Chimeric Antigen Receptor Therapies (EURE-CART)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing ...
Voir le projet
11
Participants partenaires
TERMINÉ
Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)
Date du début: 1 mai 2013, Date de fin: 31 oct. 2016,
Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl ...
Voir le projet
5
Participants partenaires
TERMINÉ
Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency (CELL-PID)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,
Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity and high risk of cancer. Treatment entails hematopoietic stem cell (HSC) transplantation from allogeneic donors, however in the absence of an HLA compatible donor, HSCT outcome is limited by delayed or suboptimal reconstitution and complications. SCID-X1 and ...
Voir le projet
20
Participants partenaires
TERMINÉ
Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases (OptiStem)
Date du début: 1 janv. 2009, Date de fin: 31 déc. 2013,
...facilities increases performance and reduces costs. Based on these considerations, a network of internationally recognized experts in muscle and epithelial cell biology, immunology, angiogenesis, and molecular pharmacology with two stem cell-based Companies has been assembled, creating a synergistic approach that will increase the chance of success for ongoing and future clinical trials with stem ...
Voir le projet
20
Participants partenaires
TERMINÉ
Advanced Teaching and TRaining for Adoptive Cell Therapy (ATTRACT)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
Considerable resources are devoted to fighting cancer throughout Europe, yet these efforts are not producing the results that health practitioners and citizens might expect. This is partly due to the fragmentation and duplication of research efforts within Member states and the lack of co-ordination at European level. However it can also be attributed to the need to retain and most importantly dev ...
Voir le projet
16
Participants partenaires
TERMINÉ
Persisting Transgenesis (PERSIST)
Date du début: 1 janv. 2009, Date de fin: 30 juin 2013,
"For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize ...
Voir le projet